ESR1 and breast cancer: Combining lasofoxifene with Palbociclib effectively inhibits tumor growth, enhancing the efficacy of ET.357 However, resistance to ET and cyclin-dependent kinase 4/6 inhibitors (CDKIs) is nearly inevitable in most ER + BC patients.